For a full catalog of our peptide services or to or to schedule an appointment, contact our office at (480) 418-3678.
Women's Health does not endorse off-label use of the medication and always advocates for lifestyle-first weight loss methods
In STEP 8, serious adverse events (SAEs) occurred in 8% of semaglutide-treated patients, in 11% of liraglutide-treated patients, and in 7% of placebo-treated patients
6.4.3 Possibility of Smaller Capsule Sizes Due to SAGs high bioavailability, smaller doses are required to achieve the same efficacy
Other serious risks include acute pancreatitis (reported as 0.23 cases per 100 patient-years), acute gallbladder disease, hypoglycemia (particularly when combined with insulin or sulfonylureas), acute kidney injury (often secondary to dehydration from gastrointestinal effects), and hypersensitivity reactions